AnaptysBio
ANAB
118 hedge funds and large institutions have $990M invested in AnaptysBio in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 10 closing their positions.
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
19% more capital invested
Capital invested by funds: $831M → $990M (+$159M)
4% more funds holding
Funds holding: 114 → 118 (+4)
6% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $1.13M
0.35% more ownership
Funds ownership: 115.29% → 115.64% (+0.35%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 38
Top Buyers
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
+$10.1M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$9.85M |
| 3 |
Millennium Management
New York
|
+$8.32M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.06M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.28M |
Top Sellers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$13.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.4M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$9.18M |
| 4 |
DM
Deerfield Management
New York
|
-$8.61M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.82M |
ANAB Hedge Fund Activity: Q4 2022 in Review
118 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q4 2022, worth a combined $990M — up 19% from $831M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ANAB positions and 10 closed out — a net gain of 5 holders — while 34 added to existing stakes and 38 trimmed.
The largest buyer was 5AM Venture Management, opening a new position worth an estimated $10.1M. The largest seller was Woodline Partners, cutting an estimated $13.1M.
- 118 institutional investors held AnaptysBio (ANAB) as of Q4 2022, up from 114 in Q3 2022.
- Funds reported $990M of AnaptysBio stock for Q4 2022, up 19% quarter-over-quarter.
- 15 funds opened new AnaptysBio positions in Q4 2022 and 10 closed out, a net change of +5 holders.
- The largest AnaptysBio buyer in Q4 2022 was 5AM Venture Management, an estimated $10.1M added.
- The largest AnaptysBio seller in Q4 2022 was Woodline Partners, an estimated $13.1M sold.
Based on aggregated 13F filings for Q4 2022.